Stayble Therapeutics AB Cash Flow Reinvestment Rate

Latest as of December 2019: 0.00x

Stayble Therapeutics AB cash flow reinvestment rate. Stayble Therapeutics AB (STABL) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr3.76 Million. Explore debt repayment capacity of Stayble Therapeutics AB to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

Skr0.00
Capex + Investments

Operating Cash Flow

Skr3.76 Million
SEK

Capital Expenditures

Skr0.00
SEK

Cash Flow Reinvestment Rate of Stayble Therapeutics AB (2019–2019)

Cash flow reinvestment rate of Stayble Therapeutics AB from 2019 to 2019. Historical reinvestment intensity for Stayble Therapeutics AB across 1 annual periods. Also explore Stayble Therapeutics AB (STABL) equity growth momentum to track the company's year-over-year net asset growth rate.

Stayble Therapeutics AB Cash Flow Reinvestment Rate by Year (2019–2019)

Stayble Therapeutics AB cash flow reinvestment rate by year from 2019 to 2019. Year-by-year capital reinvestment analysis for Stayble Therapeutics AB. For the full cash flow conversion analysis, see STABL operating cash flow.

Year Reinvestment Rate Total Reinvested (SEK) Operating CF Capex YoY Change
2019 0.00x Skr1.00K Skr289.39K Skr0.00 —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow